Moody Aldrich Partners LLC Lowers Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Moody Aldrich Partners LLC lowered its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 63.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 79,145 shares of the company's stock after selling 137,348 shares during the quarter. Moody Aldrich Partners LLC owned 0.09% of NewAmsterdam Pharma worth $2,034,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in NAMS. HB Wealth Management LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth about $224,000. JPMorgan Chase & Co. grew its holdings in NewAmsterdam Pharma by 176.9% during the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after acquiring an additional 14,280 shares during the period. Barclays PLC raised its position in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. Geode Capital Management LLC lifted its holdings in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after acquiring an additional 1,399 shares during the period. Finally, M&T Bank Corp boosted its position in NewAmsterdam Pharma by 54.1% in the 3rd quarter. M&T Bank Corp now owns 27,328 shares of the company's stock worth $454,000 after purchasing an additional 9,593 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the company's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $25.02, for a total value of $213,420.60. Following the completion of the sale, the insider now directly owns 11,812,033 shares in the company, valued at $295,537,065.66. This represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 446,730 shares of company stock valued at $11,438,695. Corporate insiders own 19.50% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on NAMS. Scotiabank lifted their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a report on Wednesday, December 11th. HC Wainwright restated a "buy" rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Needham & Company LLC reiterated a "buy" rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $41.60.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded down $0.51 during trading hours on Wednesday, reaching $20.95. 372,197 shares of the company's stock were exchanged, compared to its average volume of 621,650. The business has a fifty day moving average of $23.46 and a two-hundred day moving average of $19.95. NewAmsterdam Pharma has a 1 year low of $15.19 and a 1 year high of $27.29.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.